COMMUNIQUÉS West-GlobeNewswire

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
Notice to Convene an Extraordinary General Meeting of Genmab A/S
08/09/2026
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be [...]
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
08/09/2026
U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, [...]
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
08/09/2026
Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence [...]
Rapid Nutrition Reports 227.5% H1 Revenue Growth as Group Enters Transformational Second Half
08/09/2026
Completion of the HealthShop+ acquisition shortly before period-end establishes a materially enlarged operating and revenue base for H2 and beyond LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext [...]
Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial
08/09/2026
Single ascending dose (SAD) portion completed in healthy volunteers, with dose-proportional pharmacokinetics (PK), clear evidence of ERAP1 target engagement, and no safety or tolerability concerns observed GRWD0715 [...]
Infex Therapeutics presents new Phase IIa data for RESP-X at ERS Congress 2026, providing further evidence on exploratory efficacy endpoints supporting progression to later stage development
08/09/2026
Pa -positive NCFB patients experienced a significant reduction in annualised exacerbation rate from 3.4 in the prior 12 months to 1.2 on RESP-X treatment Only one exacerbation meeting the Hill/EMBARC criteria was [...]
Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer
08/09/2026
Dr Ambarkhane brings proven 20+ year track record advancing innovative cancer therapies through clinical development and regulatory approval Appointment strengthens Cytospire's executive leadership team as the Company [...]
PannTheraPi obtient l'approbation de l’ANSM pour l’entrée en Phase 2a de PTI5803 dans la dysplasie corticale focale
08/09/2026
L’étude de Phase 2a évaluera PTI5803, un traitement first-in-class ciblant le canal Pannexin1, chez des patients atteints de dysplasie corticale focale pharmacorésistante, une forme rare et sévère d’épilepsie Nîmes, le [...]
PannTheraPi Receives ANSM Approval to Advance PTI5803 into Phase 2a in Focal Cortical Dysplasia
08/09/2026
Phase 2a study to evaluate PannTheraPi’s first-in-class Pannexin 1-targeting therapy in patients with drug-resistant FCD, a rare and severe form of epilepsy Nîmes, France, 8 September 2026 — PannTheraPi , a clinical- [...]
First licensed treatment now available for condition behind the UK’s leading cause of horse euthanasia
08/09/2026
New veterinary treatment targets insulin dysregulation, the most common cause of laminitis in horses and ponies Bracknell, United Kingdom – Boehringer Ingelheim has announced the availability in Great Britain of the [...]
Global Healthcare Leaders Foundation Celebrates 16 Healthcare Leaders and Advances New Era of Leadership, Innovation and Global Connection
08/09/2026
NEW YORK, NY, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The Global Healthcare Leaders Foundation (GHLF) marked an important new chapter this month, recognizing 16 exceptional healthcare leaders over the course of two weeks [...]
Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio®
07/09/2026
Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio ® BREATHE prévoit d’implanter jusqu’à 229 patients dans jusqu’à 25 centres américains, suivis pendant [...]
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
07/09/2026
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio ® System BREATHE is scheduled to implant up to 229 patients at up to 25 U.S. centers, followed for up to five years, to [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
07/09/2026
Déclaration de transactions sur actions propres Paris, France (7 septembre 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 28 avril 2026, EssilorLuxottica déclare que du 31 août 2026 au [...]
EssilorLuxottica: Disclosure of transactions in own shares
07/09/2026
Disclosure of transactions in own shares Paris, France (September 7, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 28, 2026, EssilorLuxottica declares that [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
07/09/2026
Nantes, le 7 septembre 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), une société de [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 36 - 2025
07/09/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 31 août au 4 septembre 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]

Pages